Cerebral neovascularization in diabetes: Implications for stroke recovery and beyond

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 4, 2014, Pages 553-563

  Ergul, Adviye ^a,b   Abdelsaid, Mohammed ^a,b   Fouda, Abdelrahman Y ^a,b   Fagan, Susan C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Acute stroke; Angiogenesis; Arteriogenesis; Brain recovery; Diabetes

Indexed keywords

VASCULOTROPIN A;

ANGIOGENESIS; BRAIN BLOOD FLOW; BRAIN CIRCULATION; CEREBRAL NEOVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); CORONARY RISK; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIAL PROGENITOR CELL; GLYCEMIC CONTROL; NEOVASCULARIZATION (PATHOLOGY); NITRATIVE STRESS; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; ORGAN SYSTEMS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; CEREBRAL CORTEX; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; RECOVERY OF FUNCTION; STROKE;

EID: 84897578146     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.18     Document Type: Review

References (132)

1. Mink JW, Blumenschine RJ, Adams DB. Ratio of central nervous system to body metabolism in vertebrates: its constancy and functional basis. Am J Physiol 1981; 241: R203-R212.
2. Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 2011; 71: 406-424.
3. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003; 61: 39-78.
4. Cipolla MJ. The cerebral circulation. In: Granger NGaJ (ed) Integrated systems physiology: from molecule to function. Morgan & Claypool Life Sciences: San Rafael (CA), 2009.
5. Xu K, Lamanna JC. Chronic hypoxia and the cerebral circulation. J Appl Physiol 2006; 100: 725-730.
6. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 2012; 12: 148-158.
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
8. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-887.
9. Dore-Duffy P, LaManna JC. Physiologic angiodynamics in the brain. Antioxid Redox Signal 2007; 9: 1363-1371.
10. Ward NL, Moore E, Noon K, Spassil N, Keenan E, Ivanco TL et al. Cerebral angiogenic factors, angiogenesis, and physiological response to chronic hypoxia differ among four commonly used mouse strains. J Appl Physiol 2007; 102: 1927-1935.
11. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006; 10: 45-55.
12. Drake CJ. Embryonic and adult vasculogenesis. Birth Defects Res C Embryo Today 2003; 69: 73-82.
13. Silvestre JS, Smadja DM, Levy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev 2013; 93: 1743-1802.
14. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.
15. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180.
16. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes 2011; 60: 9-16.
17. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010; 12: 943-953.
18. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 2013; 3: a006569.
19. Arese M, Serini G, Bussolino F. Nervous vascular parallels: axon guidance and beyond. Int J Dev Biol 2011; 55: 439-445.
20. Lee CY, Bautch VL. Ups and downs of guided vessel sprouting: the role of polarity. Physiology (Bethesda) 2011; 26: 326-333.
21. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-478.
22. Adams RH, Eichmann A. Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2010; 2: a001875.
23. Park KW, Morrison CM, Sorensen LK, Jones CA, Rao Y, Chien CB et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol 2003; 261: 251-267.
24. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008; 14: 448-453.
25. Kaur S, Samant GV, Pramanik K, Loscombe PW, Pendrak ML, Roberts DD et al. Silencing of directional migration in roundabout4 knockdown endothelial cells. BMC Cell Biol 2008; 9: 61.
26. Simons M. Angiogenesis: where do we stand now? Circulation 2005; 111: 1556-1566.
27. Cai W, Schaper W. Mechanisms of arteriogenesis. Acta Biochim Biophys Sin 2008; 40: 681-692.
28. van Oostrom MC, van Oostrom O, Quax PH, Verhaar MC, Hoefer IE. Insights into mechanisms behind arteriogenesis: what does the future hold? J Leukoc Biol 2008; 84: 1379-1391.
29. Fung E, Helisch A. Macrophages in collateral arteriogenesis. Front Physiol 2012; 3: 353.
30. Li W, Prakash R, Kelly-Cobbs AI, Ogbi S, Kozak A, El-Remessy AB et al. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 2010; 59: 228-235.
31. Prakash R, Somanath PR, El-Remessy AB, Kelly-Cobbs A, Stern JE, Dore-Duffy P et al. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes 2012; 61: 1533-1542.
32. Prakash R, Johnson M, Fagan SC, Ergul A. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. PLoS ONE 2013; 8: e56264.
33. Beauquis J, Homo-Delarche F, Giroix MH, Ehses J, Coulaud J, Roig P et al. Hippocampal neurovascular and hypothalamic-pituitary-adrenal axis alterations in spontaneously type 2 diabetic GK rats. Exp Neurol 2010; 222: 125-134.
34. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366: 1227-1239.
35. Whitmire W, Al-Gayyar MM, Abdelsaid M, Yousufzai BK, El-Remessy AB. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far. Mol Vis 2011; 17: 300-308.
36. Loukovaara S, Robciuc A, Holopainen JM, Lehti K, Pessi T, Liinamaa J et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 2013; 91: 531-539.
37. Yoshida S, Nakama T, Ishikawa K, Arima M, Tachibana T, Nakao S et al. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012; 53: 6997-7003.
38. Rodrigues M, Xin X, Jee K, Babapoor-Farrokhran S, Kashiwabuchi F, Ma T et al. VEGF secreted by hypoxic muller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy. Diabetes 2013; 62: 3863-3873.
39. Coorey NJ, Shen W, Chung SH, Zhu L, Gillies MC. The role of glia in retinal vascular disease. Clin Exp Optom 2012; 95: 266-281.
40. Ali TK, Al-Gayyar MM, Matragoon S, Pillai BA, Abdelsaid MA, Nussbaum JJ et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 2011; 54: 657-668.
41. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 2009; 37(Pt 6): 1207-1213.
42. Yun J, Rocic P, Pung YF, Belmadani S, Carrao AC, Ohanyan V et al. Redoxdependent mechanisms in coronary collateral growth: the "redox window" hypothesis. Antioxid Redox Signal 2009; 11: 1961-1974.
43. Rocic P. Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome? Vascul Pharmacol 2012; 57: 179-186.
44. Trask AJ, Delbin MA, Katz PS, Zanesco A, Lucchesi PA. Differential coronary resistance microvessel remodeling between type 1 and type 2 diabetic mice: impact of exercise training. Vascul Pharmacol 2012; 57: 187-193.
45. Toyota E, Matsunaga T, Chilian WM. Myocardial angiogenesis. Mol Cell Biochem 2004; 264: 35-44.
46. Chilian WM, Penn MS, Pung YF, Dong F, Mayorga M, Ohanyan V et al. Coronary collateral growth - back to the future. J Mol Cell Cardiol 2012; 52: 905-911.
47. El-Azab MF, Hazem RM, Moustafa YM. Role of simvastatin and/or antioxidant vitamins in therapeutic angiogenesis in experimental diabetic hindlimb ischemia: effects on capillary density, angiogenesis markers, and oxidative stress. Eur J Pharmacol 2012; 690: 31-41.
48. Altavilla D, Bitto A, Polito F, Marini H, Minutoli L, Di Stefano V et al. Polydeoxyribonucleotide (PDRN): a safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers. Cardiovasc Hematol Agents Med Chem 2009; 7: 313-321.
49. Emanueli C, Monopoli A, Kraenkel N, Meloni M, Gadau S, Campesi I et al. Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice. Br J Pharmacol 2007; 150: 873-882.
50. Min W, Yamanaka N. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Arch A Pathol Anat Histopathol 1993; 423: 201-207.
51. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009; 58: 1471-1478.
52. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005; 54: 2891-2903.
53. Osterby R, Hartmann A, Bangstad HJ. Structural changes in renal arterioles in Type I diabetic patients. Diabetologia 2002; 45: 542-549.
54. Guo M, Ricardo SD, Deane JA, Shi M, Cullen-McEwen L, Bertram JF. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 2005; 207: 813-821.
55. Advani A, Gilbert RE. The endothelium in diabetic nephropathy. Semin Nephrol 2012; 32: 199-207.
56. LaManna JC. Hypoxia in the central nervous system. Essays Biochem 2007; 43: 139-151.
57. Kelly-Cobbs AI, Prakash R, Coucha M, Knight RA, Li W, Ogbi SN et al. Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone. J Pharmacol Exp Ther 2012; 342: 407-415.
58. Ergul A, Li W, Elgebaly MM, Bruno A, Fagan SC. Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature. Vascul Pharmacol 2009; 51: 44-49.
59. Greenberg DA, Jin K. Vascular endothelial growth factors (VEGFs) and stroke. Cell Mol Life Sci 2013; 70: 1753-1761.
60. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169-183.
61. Graupera M, Potente M. Regulation of angiogenesis by PI3K signaling networks. Exp Cell Res 2013; 319: 1348-1355.
62. Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 2013; 92: 1037-1045.
63. Abdelsaid MA, Pillai BA, Matragoon S, Prakash R, Al-Shabrawey M, El-Remessy AB. Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther 2010; 332: 125-134.
64. Ali TK, El-Remessy AB. Diabetic retinopathy: current management and experimental therapeutic targets. Pharmacotherapy 2009; 29: 182-192.
65. El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M, Behzadian MA, Ghaly N et al. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitrationindependent mechanism in endothelial cells. FASEB J 2007; 21: 2528-2539.
66. El-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 2005; 118(Pt 1): 243-252.
67. Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol 2009; 11: 1325-1331.
68. London NR, Li DY. Robo4-dependent Slit signaling stabilizes the vasculature during pathologic angiogenesis and cytokine storm. Curr Opin Hematol 2011; 18: 186-190.
69. Koch AW, Mathivet T, Larrivee B, Tong RK, Kowalski J, Pibouin-Fragner L et al. Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell 2011; 20: 33-46.
70. Zhang X, Yu J, Kuzontkoski PM, Zhu W, Li DY, Groopman JE. Slit2/Robo4 signaling modulates HIV-1 gp120-induced lymphatic hyperpermeability. PLoS Pathog 2012; 8: e1002461.
71. Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV et al. Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporationfacilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 2008; 217: 319-327.
72. Jung YJ, Kim DH, Lee AS, Lee S, Kang KP, Lee SY et al. Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia- reperfusioninduced acute kidney injury. Am J Physiol Renal Physiol 2009; 297: F952-F960.
73. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476-481.
74. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314: 15-23.
75. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006; 312: 623-629.
76. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-523.
77. Gaengel K, Genove G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 630-638.
78. Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S et al. Endothelial Wnt/ beta-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 2012; 209: 1611-1627.
79. Dalkara T, Gursoy-Ozdemir Y, Yemisci M. Brain microvascular pericytes in health and disease. Acta Neuropathol 2011; 122: 1-9.
80. Ahmad FK, He Z, King GL.. Molecular targets of diabetic cardiovascular complications. Curr Drug Targets 2005; 6: 487-494.
81. Kota SK, Meher LK, Jammula S, Kota SK, Krishna SV, Modi KD. Aberrant angiogenesis: The gateway to diabetic complications. Indian J Endocrinol Metab 2012; 16: 918-930.
82. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood 2003; 102: 1740-1742.
83. Kim YW, West XZ, Byzova TV. Inflammation and oxidative stress in angiogenesis and vascular disease. J Mol Med (Berl) 2013; 91: 323-328.
84. Wang X, Abraham S, McKenzie JA, Jeffs N, Swire M, Tripathi VB et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 2013; 499: 306-311.
85. Okuno Y, Nakamura-Ishizu A, Otsu K, Suda T, Kubota Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med 2012; 18: 1208-1216.
86. Kida Y, Tchao BN, Yamaguchi I. Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease. Pediatr Nephrol 2013; doi:10.1007/ 500467-013-2430-4 (e-pub ahead of print).
87. Fligny C, Duffield JS. Activation of pericytes: recent insights into kidney fibrosis and microvascular rarefaction. Curr Opin Rheumatol 2013; 25: 78-86.
88. Hayashi T, Noshita N, Sugawara T, Chan PH. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J Cereb Blood Flow Metab 2003; 23: 166-180.
89. Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S et al. A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 1997; 28: 564-573.
90. Ergul A, Alhusban A, Fagan SC. Angiogenesis: a harmonized target for recovery after stroke. Stroke 2012; 43: 2270-2274.
91. Baba T, Kameda M, Yasuhara T, Morimoto T, Kondo A, Shingo T et al. Electrical stimulation of the cerebral cortex exerts antiapoptotic, angiogenic, and antiinflammatory effects in ischemic stroke rats through phosphoinositide 3-kinase/ Akt signaling pathway. Stroke 2009; 40: e598-e605.
92. Espinera AR, Ogle ME, Gu X, Wei L. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience 2013; 247: 1-11.
93. Ding G, Jiang Q, Li L, Zhang L, Zhang Z, Lu M et al. Longitudinal magnetic resonance imaging of sildenafil treatment of embolic stroke in aged rats. Stroke 2011; 42: 3537-3541.
94. Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke 2007; 38: 3032-3039.
95. Ishikawa H, Tajiri N, Shinozuka K, Vasconcellos J, Kaneko Y, Lee HJ et al. Vasculogenesis in experimental stroke after human cerebral endothelial cell transplantation. Stroke 2013; 44: 3473-3481.
96. Reitmeir R, Kilic E, Kilic U, Bacigaluppi M, ElAli A, Salani G et al. Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity. Brain 2011; 134(Pt 1): 84-99.
97. Madinier A, Bertrand N, Rodier M, Quirie A, Mossiat C, Prigent-Tessier A et al. Ipsilateral versus contralateral spontaneous post-stroke neuroplastic changes: involvement of BDNF? Neuroscience 2013; 231: 169-181.
98. Li WL, Fraser JL, Yu SP, Zhu J, Jiang YJ, Wei L. The role of VEGF/VEGFR2 signaling in peripheral stimulation-induced cerebral neurovascular regeneration after ischemic stroke in mice. Exp Brain Res 2011; 214: 503-513.
99. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A et al. Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS ONE 2011; 6: e24551.
100. Prakash R, Li W, Qu Z, Johnson MA, Fagan SC, Ergul A. Vascularization pattern after ischemic stroke is different in control versus diabetic rats: relevance to stroke recovery. Stroke 2013; 44: 2875-2882.
101. Ergul A, Elgebaly MM, Middlemore ML, Li W, Elewa H, Switzer JA et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol 2007; 7: 33.
102. Elewa HF, Kozak A, El-Remessy AB, Frye RF, Johnson MH, Ergul A et al. Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J Pharmacol Exp Ther 2009; 330: 532-540.
103. Elgebaly MM, Prakash R, Li W, Ogbi S, Johnson MH, Mezzetti EM et al. Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling. J Cereb Blood Flow Metab 2010; 30: 1928-1938.
104. Cui X, Chopp M, Zacharek A, Ye X, Roberts C, Chen J. Angiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral stroke. Neurobiol Dis 2011; 43: 285-292.
105. Ye X, Chopp M, Cui X, Zacharek A, Cui Y, Yan T et al. Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. Exp Neurol 2011; 232: 299-308.
106. Chen Z, Gao C, Hua Y, Keep RF, Muraszko K, Xi G. Role of iron in brain injury after intraventricular hemorrhage. Stroke 2010; 42: 465-470.
107. Lee JY, Keep RF, He Y, Sagher O, Hua Y, Xi G. Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. J Cereb Blood Flow Metab 2011; 30: 1793-1803.
108. Gu Y, Hua Y, He Y, Wang L, Hu H, Keep RF et al. Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage. Acta Neurochir Suppl 2011; 111: 123-128.
109. Mehta SH, Webb RC, Ergul A, Tawak A, Dorrance AM. Neuroprotection by tempol in a model of iron-induced oxidative stress in acute ischemic stroke. Am J Physiol Regul Integr Comp Physiol 2004; 286: R283-R288.
110. Lin S, Zhong Q, Lv FL, Zhou Y, Li JQ, Wang JZ et al. Heme activates TLR4- mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. J Neuroinflammation 2012; 9: 46.
111. Wolfson RK, Chiang ET, Garcia JG. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 2011; 81: 189-197.
112. Zhu M, Bi X, Jia Q, Shangguan S. The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor. Biomed Pharmacother 2010; 64: 208-213.
113. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703.
114. Schabitz WR, Laage R, Vogt G, Koch W, Kollmar R, Schwab S et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke 2010; 41: 2545-2551.
115. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
116. Chen J, Ye X, Yan T, Zhang C, Yang XP, Cui X et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats. Stroke 2011; 42: 3551-3558.
117. Li Calzi S, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, Grant MB.. EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res 2010; 79: 207-216.
118. Jarajapu YP, Grant MB. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res 2010; 106: 854-869.
119. Buschmann IR, Busch HJ, Mies G, Hossmann KA. Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colonystimulating factor. Circulation 2003; 108: 610-615.
120. Chen J, Cui X, Zacharek A, Ding GL, Shehadah A, Jiang Q et al. Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. J Cereb Blood Flow Metab 2009; 29: 911-920.
121. Zacharek A, Chen J, Cui X, Yang Y, Chopp M. Simvastatin increases notch signaling activity and promotes arteriogenesis after stroke. Stroke 2009; 40: 254-260.
122. Sugiyama Y, Yagita Y, Oyama N, Terasaki Y, Omura-Matsuoka E, Sasaki T et al. Granulocyte colony-stimulating factor enhances arteriogenesis and ameliorates cerebral damage in a mouse model of ischemic stroke. Stroke 2011; 42: 770-775.
123. Rink C, Christoforidis G, Khanna S, Peterson L, Patel Y, Khanna S et al. Tocotrienol vitamin E protects against preclinical canine ischemic stroke by inducing arteriogenesis. J Cereb Blood Flow Metab 2011; 31: 2218-2230.
124. Cui X, Chopp M, Zacharek A, Dai J, Zhang C, Yan T et al. Combination treatment of stroke with sub-therapeutic doses of Simvastatin and human umbilical cord blood cells enhances vascular remodeling and improves functional outcome. Neuroscience 2012; 227: 223-231.
125. Cui X, Chopp M, Zacharek A, Cui Y, Roberts C, Chen J. The neurorestorative benefit of GW3965 treatment of stroke in mice. Stroke 2013; 44: 153-161.
126. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-1737.
127. Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005; 25: 281-290.
128. Gertz K, Priller J, Kronenberg G, Fink KB, Winter B, Schrock H et al. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase- dependent augmentation of neovascularization and cerebral blood flow. Circ Res 2006; 99: 1132-1140.
129. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 2007; 62: 49-58.
130. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA et al. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J Cereb Blood Flow Metab 2008; 28: 1440-1448.
131. Wang Z, Tsai LK, Munasinghe J, Leng Y, Fessler EB, Chibane F et al. Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke 2012; 43: 2430-2436.
132. Yang Y, Thompson JF, Taheri S, Salayandia VM, McAvoy TA, Hill JW et al. Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J Cereb Blood Flow Metab 2013; 33: 1104-1114.